Journal of Clinical Endocrinology & Metabolism, Vol 64, 328-333, Copyright © 1987 by Endocrine Society

ARTICLES

Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole

FJ Holland, SE Kirsch and R Selby

Three boys, 5.0-7.4 yr of age, with clinical and biochemical features consistent with familial gonadotropin-independent precocious puberty ("testotoxicosis") were treated with the antifungal drug ketoconazole in a dose of 200 mg every 8 h. Serum testosterone levels fell significantly within 24 h in all three patients, with reciprocal changes in serum 17-hydroxyprogesterone, consistent with inhibition of C17-20 lyase activity. However, after 1-3 months of continuing treatment, an "escape" phenomenon occurred, characterized by progressive increases in serum LH, FSH, and testosterone concentrations. Furthermore, for the first time, a marked pubertal-type LH response was found after GnRH administration in contrast to the absent response consistently found in all patients before ketoconazole therapy. Combination treatment with ketoconazole and the GnRH analog buserelin resulted in restoration of pituitary and gonadal hormone concentrations to the upper range of normal for prepubertal children. We hypothesize that the advanced state of maturation of the boys in this study [mean bone age, 13.2 +/- 0.8 (+/- SE) yr] was the major contributing factor to this escape, with the set-point of the GnRH pulse generator (gonadostat) functioning at the adult level of sensitivity. Such escape may limit the successful use of ketoconazole alone. These data together with evidence of normal testosterone responses to hCG during ketoconazole therapy indicate that in testotoxicosis, pituitary and gonadal receptors are functionally intact, with appropriate negative feedback relationships.

This article has been cited by other articles:

				L. Soriano-Guillen, N. Lahlou, G. Chauvet, M. Roger, J. L. Chaussain, and J. C. Carel Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 147 - 151. [Abstract] [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]

				A. Flor-Cisneros, E. W. Leschek, D. P. Merke, K. M. Barnes, M. Coco, G. B. Cutler Jr., and J. Baron In Boys with Abnormal Developmental Tempo, Maturation of the Skeleton and the Hypothalamic-Pituitary-Gonadal Axis Remains Synchronous J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 236 - 241. [Abstract] [Full Text] [PDF]

				E. W. Leschek, J. Jones, K. M. Barnes, S. C. Hill, and G. B. Cutler Jr. Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 175 - 178. [Abstract] [Full Text]

				J. Gromoll, C.-J. Partsch, M. Simoni, V. Nordhoff, W. G. Sippell, E. Nieschlag, and B. B. Saxena A Mutation in the First Transmembrane Domain of the Lutropin Receptor Causes Male Precocious Puberty J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 476 - 480. [Abstract] [Full Text]

				P. A. Clark and W. L. Clarke Testotoxicosis: An Unusual Presentation and Novel Gene Mutation Clinical Pediatrics, May 1, 1995; 34(5): 271 - 274. [PDF]

				P. A. Lee Advances in the Management of Precocious Puberty Clinical Pediatrics, January 1, 1994; 33(1): 54 - 61. [PDF]